Polycythemia Vera
Pipeline by Development Stage
Drug Modality Breakdown
Hematology is a $3.6B market dominated by a single blockbuster (IMBRUVICA at 65% share) with moderate consolidation among 15 companies.
Key Trends
- IMBRUVICA monopoly creates revenue concentration risk but sustained peak-cycle performance
- Multiple patent cliffs 2027-2030 will drive significant biosimilar/generic competition
- 1,109 active trials signal robust pipeline activity in underexplored indications like myelofibrosis and platelet disorders
Career Verdict
Hematology offers solid commercial and medical affairs opportunities in a stable, high-margin market, but pipeline diversity remains limited outside oncology-adjacent BTK inhibitors.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 65% | Peak | Stable | 8.6yr |
| 2 | PROMACTA (eltrombopag olamine) | Novartis | $558M | 15% | LOE Approaching | Declining | 1.4yr |
| 3 | AURYXIA (ferric citrate) | Ipsen | $183M | 5% | Peak | Stable | 3.8yr |
| 4 | OXBRYTA (voxelotor) | Pfizer | $101M | 3% | Peak | Growing | 11.1yr |
| 5 | DOPTELET (avatrombopag maleate) | Unknown | $96M | 3% | LOE Approaching | Declining | 0.9yr |
Drug Class Breakdown
dominates market, stable
multiple players, patent risk
niche, CKD-focused
sickle cell focused, growing
myeloproliferative neoplasms, early growth
legacy class, biosimilar pressure
biosimilar-saturated, mature
Career Outlook
StableHematology is a stable, mature therapeutic area with predictable commercial demand but limited innovation upside. The market is defensible by IMBRUVICA (peak through 2035) and near-term patent cliff risks (2027-2030) will create managed-care and payer expertise needs. Long-term career growth depends on successful pipeline diversification beyond BTK inhibitors and late-stage pipeline expansion.
Breaking In
Enter via Clinical Operations or Medical Affairs to build hematology disease knowledge; specialize early in rare indications (ITP, myelofibrosis) where differentiation exists.
For Experienced Professionals
Experienced professionals should target Bristol Myers Squibb, Novartis, or GSK to lead patent-cliff transition strategies and next-generation mechanism adoption (JAK, TPO agonists).
In-Demand Skills
Best For
Hiring Landscape
Hematology hiring is concentrated in Commercial (24 roles, $201K avg) and Medical Affairs (15 roles, $204K avg) functions, reflecting a mature market focused on market penetration and specialist education. Labcorp, Bristol Myers Squibb, and Regeneron lead hiring, suggesting demand in diagnostics, R&D, and rare disease support. Notably low R&D hiring (7 roles, $147K avg) indicates limited pipeline-driven growth outside established players.
Top Hiring Companies
By Department
Commercial and Medical Affairs roles offer highest compensation and most openings; entry-level clinical operations salaries lag at $91K, while R&D roles are scarce and lower-paid.
On Market (4)
Approved therapies currently available
Competitive Landscape
19 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 33 trials with date data
Clinical Trials (33)
Total enrollment: 4,886 patients across 33 trials
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients
AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
A Study of Rusfertide in Adults With Polycythemia Vera in China
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
A Study of Rusfertide in Japanese Adults With Polycythemia Vera
A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Pomalidomide for Myelofibrosis Patients
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations
Study to Assess SLN124 in Patients With Polycythemia Vera
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
A Study of GLB-001 in Patients With Myeloid Malignancies
Safety Evaluation Study for Patients With Polycythemia Vera
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
LOW-PV Continuation
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)
Related Jobs in Hematology
Senior Field Applications Specialist (Territory: Central New York)
Senior Field Applications Specialist (Territory: Central New York)
Global Clinical Program Lead, Hematology
Medical Director
Senior Clinical Trial Manager
Director, SYFOVRE Market Access Strategy
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.